title: Varenicline and cardiovascular adverse events: a perspective review.
abstract: Smoking is a leading preventable cause of mortality and morbidity. Varenicline, a first-line smoking cessation aid, is used widely to achieve successful quit rates in smokers. A number of studies and systematic reviews have evaluated the safety profile of the drug. To date, three systematic reviews by Singh and colleagues, Prochaska and Hilton, and Ware and colleagues, published between 2011 and 2013, have evaluated serious cardiovascular adverse events with varenicline use. Even though all three reviews demonstrated that serious cardiovascular adverse events were nominally more frequent in varenicline-treated patients when compared with placebo, a significantly increased event rate was found only in the review by Singh and colleagues. The three reviews included similar trials but differed in the evaluation of outcomes and performance of summary statistic computation. Though the evidence from the two most recent systematic reviews demonstrated that risk of serious cardiovascular events might not be increased with varenicline use, the US Food and Drug Administration has advised prescription with caution combined with close monitoring and education of patients until more conclusive evidence is available. Results of these reviews cannot be generalized to patients with unstable cardiac conditions.
authors.affiliation: Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Yohalakshmi
authors.initials: Y
authors.lastname: Chelladurai
authors.affiliation: Department of Medicine, Johns Hopkins University, E7144, 624 N Wolfe St, Baltimore, MD 21205, USA.
authors.forename: Sonal
authors.initials: S
authors.lastname: Singh
keywords: Champix; Chantix; adverse events; cardiovascular; review; varenicline
references.citation: JAMA. 2003 Jul 2;290(1):86-97
references.pmid: 12837716
references.citation: Ann Med. 2012 Sep;44(6):588-97
references.pmid: 22860882
references.citation: Neuropsychiatr Dis Treat. 2008 Apr;4(2):353-63
references.pmid: 18728741
references.citation: Circulation. 2010 Jan 19;121(2):221-9
references.pmid: 20048210
references.citation: CMAJ. 2011 Sep 6;183(12):1359-66
references.pmid: 21727225
references.citation: Respir Care. 2008 Sep;53(9):1217-22
references.pmid: 18807274
references.citation: Cochrane Database Syst Rev. 2004;(1):CD003041
references.pmid: 14974003
references.citation: Am J Ther. 2013 May-Jun;20(3):235-46
references.pmid: 23615317
references.citation: Neuropharmacology. 2007 Mar;52(3):985-94
references.pmid: 17157884
references.citation: BMJ. 2012 May 04;344:e2856
references.pmid: 22563098
references.citation: Cochrane Database Syst Rev. 2013 May 31;(5):CD009329
references.pmid: 23728690
references.citation: Am J Gastroenterol. 2009 Mar;104(3):546-51
references.pmid: 19262513